Screener
Design Therapeutics, Inc. DSGN Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-187063
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from the issuance of common stock in at-the-market offering, net of issuance costs | 19,907 | — |
| Proceeds from the exercise of stock options | 27 | 23 |
| Net cash provided by financing activities | 19,934 | 23 |
| Net decrease in cash and cash equivalents | (4,086) | (8,896) |
| Cash and cash equivalents at beginning of period | 16,856 | 22,563 |
| Cash and cash equivalents at end of period | $12,770 | $13,667 |
| Supplemental disclosures | ||
| Increase in right-of-use-asset and operating lease liability related to lease amendment | $1,295 | — |
Item 1. Financial Statements.
FAQ
- What is Design Therapeutics, Inc.'s net change in cash?
- Design Therapeutics, Inc. (DSGN) reported net change in cash of -$4.09M in Q1 2026.
- How has Design Therapeutics, Inc.'s net change in cash changed year-over-year?
- Design Therapeutics, Inc.'s net change in cash increased by 54.1% year-over-year, from -$8.9M to -$4.09M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Design Therapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude